A Chinese team of researchers has discovered the first highly effective neutralized monoclonal antibody in the N-side domain of targeted stingprotein, which provides a new effective target for the development of the new crown drug, the Chinese research team said in a paper published online in the American journal Science. Chen Wei, a member of the Institute of Military Medicine of the Chinese Academy of Military Sciences, is one of the authors of the paper.
The paper said the researchers isolated and identified monoclonal antibodies from 10 patients with new coronal stages of rehabilitation and found that three antibodies showed neutralizing the activity against the new coronavirus, one of which showed high school and ability.
Neutralizing antibodies is a protective class of antibodies produced by the body in response to antigen stimulation. At present, several research teams around the world have focused on the receptor binding domain of the neo-coronavirus stingprotein for drug design and mechanism research of the new coronavirus. The Chinese team’s study found that the N-end domain is a new vulnerable epimoste of the new coronavirus sting protein by identifying efficient neutralizing monoclonal antibodies in the N-end domain of the stingprotein, which provides a new effective target for therapeutic antibodies and other drug designs.